14 min listen
How does maximizing shareholder value distort drug development?
FromThe BMJ Podcast
ratings:
Length:
18 minutes
Released:
Jul 28, 2016
Format:
Podcast episode
Description
With the emergence of sofobuvir, a new direct acting antiviral, treatment for Hepatitis C infection is currently undergoing it's greatest change since the discovery of the virus 25 years ago.
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale.
Read the full analysis:
http://www.bmj.com/content/354/bmj.i3718
However Gilead, who manufacture the treatment, are under fire for the cost of the druge - around $90 000 for a course of treatment.
Victor Roy, doctoral researcher at the University of Cambridge, discusses how the new drug was discovered and came to market, and what happened to the profits from sale.
Read the full analysis:
http://www.bmj.com/content/354/bmj.i3718
Released:
Jul 28, 2016
Format:
Podcast episode
Titles in the series (100)
Suspected heart failure: Mabel Chew, practice editor at the BMJ, talks to Tushar Kotecha, a cardiology specialist registrar at Charing Cross Hospital in London, about when to suspect heart failure, and how to diagnose the condition. by The BMJ Podcast